Skip to content
October 16, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Patient Advocacy and Support
  • A Global Beacon of Hope: 325 Landmarks to Illuminate for National Metastatic Breast Cancer Awareness Day
  • Patient Advocacy and Support

A Global Beacon of Hope: 325 Landmarks to Illuminate for National Metastatic Breast Cancer Awareness Day

Layla Zulfa October 16, 2026 8 minutes read
a-global-beacon-of-hope-325-landmarks-to-illuminate-for-national-metastatic-breast-cancer-awareness-day-1

NEW YORK, NY — As the world enters the second week of October, a month traditionally synonymous with pink ribbons and messages of early detection, a growing global movement is shifting the spotlight toward a more sobering reality. On October 13, 2026, in observance of National Metastatic Breast Cancer Awareness Day, the #LightUpMBC campaign will orchestrate a monumental display of solidarity. More than 325 landmarks across 50 U.S. states and 20 countries are set to illuminate in the symbolic colors of teal, green, and pink.

The initiative, spearheaded by METAvivor Research and Support, aims to bring visibility to Metastatic Breast Cancer (MBC)—also known as Stage 4—the only form of breast cancer that currently has no cure. While the broader "Pink October" narrative often focuses on "winning the fight" and "finishing treatment," the #LightUpMBC campaign serves as a reminder that for those with metastatic disease, treatment never ends.

Main Facts: Turning Awareness into Action

Metastatic Breast Cancer occurs when breast cancer spreads beyond the initial site in the breast to distant organs, most commonly the bones, liver, lungs, or brain. Despite being located in other parts of the body, the disease remains breast cancer and is treated as such. It is a terminal diagnosis, yet it remains significantly underfunded in the broader landscape of oncological research.

METAvivor, the non-profit organization behind the campaign, is unique in its mission: it is the only organization in the United States that exclusively funds Stage 4 MBC research. The #LightUpMBC campaign is its signature public-facing event, combining large-scale visual advocacy with a high-production digital broadcast.

On the evening of October 13, the global landscape will be transformed. From the towering heights of One World Trade Center in New York City and the Willis Tower in Chicago to international sites like the Mactan-Cebu Airport in the Philippines and the Ness Bridge in Scotland, the world will glow in a specific tri-color palette.

  • Teal represents healing and spirituality.
  • Green represents the triumph of spring over winter, symbolizing life and renewal.
  • Pink signifies that the cancer originated in the breast.

The campaign’s central event, "#LightUpMBC Live," will stream for free at 8 p.m. ET / 5 p.m. PT. Hosted by MBC patient and advocate Tami Eagle Bowling and Broadway star Kara Lindsay, the program will blend scientific education, patient testimonials, and world-class musical performances to raise funds that go directly toward research grants.

Chronology: From a Single Bridge to a Global Phenomenon

The origins of #LightUpMBC are rooted in a personal story of friendship and loss. The campaign was founded by Laura Inahara in honor of her best friend, Jessica Moore. Jessica was diagnosed with metastatic breast cancer at the age of 32 and passed away just four years later at 36.

In 2017, Jessica had a modest goal: she wanted to see one local landmark lit up in MBC awareness colors to show patients they were not forgotten. That year, the Memorial Bridge, which connects Portsmouth, New Hampshire, to Kittery, Maine, became the first landmark to shine for MBC.

Since Jessica’s passing, the movement has grown exponentially:

  • 2017–2019: The campaign began as a grassroots effort, securing a handful of landmarks in the Northeast United States.
  • 2020: Despite the global pandemic, the campaign transitioned into a virtual space, launching the first "#LightUpMBC Live" broadcast to reach patients isolated at home.
  • 2021–2025: The number of participating landmarks surged from dozens to hundreds, expanding into Europe, Asia, and South America. Fundraising efforts surpassed the $2 million mark.
  • 2026: The campaign reaches its largest scale to date, with over 325 landmarks confirmed. To date, the initiative has raised over $2.7 million for critical research.

Supporting Data: The Stark Reality of Stage 4

The necessity of the #LightUpMBC campaign is underscored by harrowing statistics provided by the National Cancer Institute and the American Cancer Society. In 2026, it is estimated that 42,670 people in the United States alone will die from breast cancer. This averages out to approximately 117 deaths every single day.

Virtually all of these deaths are the result of metastatic disease. While the five-year survival rate for localized breast cancer is nearly 99%, that number drops precipitously to approximately 30% for those diagnosed with Stage 4.

Key data points driving the METAvivor mission include:

  1. The Funding Gap: Historically, only 2% to 5% of all funds raised for breast cancer research are directed toward studying metastatic disease. The vast majority of funding is allocated toward prevention, early detection, and early-stage treatment.
  2. The De Novo Factor: While many believe MBC only happens to those who "miss" their mammograms, a significant portion of patients are diagnosed "de novo," meaning they are Stage 4 from their very first diagnosis.
  3. Recurrence: Even for those who catch the disease early (Stage 1, 2, or 3) and complete treatment, the cancer can return as metastatic disease months, years, or even decades later. There is currently no way to predict or completely prevent this recurrence.

METAvivor addresses these gaps through a rigorous scientific peer-review process. Every research grant is vetted by both leading oncologists and patient advocates to ensure the projects have the highest potential to extend and improve the lives of those living with MBC.

Official Responses: Voices from the Front Lines

The leadership of METAvivor emphasizes that while the lights are beautiful, the purpose is survival.

“When I was diagnosed with metastatic breast cancer in 2013, I certainly didn’t think I’d still be here 13 years later,” said Dr. Kelly Shanahan, METAvivor Board President. “My hope and the hope of so many others lies in research, and METAvivor funded research is increasingly important these days. #LightUpMBC is the biggest contributor to this research, and is also a way to bring us together as a community.”

For Laura Inahara, the campaign’s founder, the growth of the movement is a bittersweet testament to her friend’s legacy. “Jessica hoped to illuminate one local landmark. Today, her legacy helps families around the world shine a light for the people they love, teach patients with MBC how to advocate for themselves and has now raised over $2.7 million for critical MBC research.”

The 2026 live broadcast will also feature a heavy presence from the arts community, highlighting the universal impact of the disease. Two-time Tony Award winner Victoria Clark and Tony Award nominee Dorian Harewood are among the performers scheduled to appear. Their involvement signals a growing awareness in the philanthropic community that MBC requires a dedicated, specialized focus.

Implications: Shifting the Narrative of Advocacy

The #LightUpMBC campaign represents a broader shift in how society views cancer advocacy. For decades, the "War on Cancer" has focused on the "Survivor" — the individual who rings the bell and moves on. #LightUpMBC introduces the "Thriver" or the "Forever Fighter," individuals who live in a perpetual state of treatment.

1. The End of "Pink-Washing"
The campaign serves as a critique of "pink-washing"—the corporate use of pink ribbons to sell products without contributing to the research needed to save lives. By using teal and green alongside pink, METAvivor is reclaiming the month of October for the 30% of breast cancer patients who will eventually metastasize.

2. Policy and Research Priorities
The visibility of 325 illuminated landmarks puts pressure on federal and private funding bodies to re-evaluate their portfolios. As public awareness grows, there is an increasing demand for the National Institutes of Health (NIH) and other major organizations to increase the percentage of funding dedicated specifically to Stage 4 research.

3. Global Patient Connectivity
The "Live" component of the campaign utilizes modern streaming technology to bridge the gap between patients in rural areas and world-class specialists. By featuring scientific perspectives alongside patient stories, the broadcast empowers patients to become their own advocates, learning about the latest clinical trials and therapeutic breakthroughs.

4. The Path to a Chronic Condition
The ultimate goal of METAvivor is to transform MBC from a terminal illness into a manageable, chronic condition—similar to HIV/AIDS or Type 1 diabetes. The funds raised on October 13 are a direct investment in that future. With 100% of net proceeds from the campaign going toward research, the 2026 event is expected to fund several new grants that could lead to the next breakthrough in targeted therapy or immunotherapy.

How to Participate

As the sun sets on October 13, the public is encouraged to engage with the campaign by:

  • Photographing Landmarks: Supporters are asked to take photos of participating landmarks and share them on social media using the hashtags #LightUpMBC and #METAvivor.
  • Watching the Stream: The live broadcast will be available on METAvivor’s YouTube and Facebook channels, as well as through the LiveOne streaming platform.
  • Donating: Contributions can be made directly at www.lightupmbc.org, where 100% of net proceeds are dedicated to MBC research.

In a world often saturated with fleeting digital trends, #LightUpMBC stands as a physical and luminous testament to the 42,670 lives lost annually and the hundreds of thousands more who continue to live, hope, and advocate in the face of a terminal diagnosis. This October 13, the message is clear: awareness is not enough; only research will save lives.


About METAvivor Research and Support Inc.:
METAvivor is a 501(c)(3) non-profit organization dedicated to the specific fight of women and men living with stage 4 metastatic breast cancer. It is the only organization that dedicated 100% of its net/targeted donations to metastatic breast cancer research.

About #LightUpMBC:

LightUpMBC is a global landmark campaign and digital broadcast designed to shine a light on the need for metastatic breast cancer research. Since its inception, it has become the premier global event for MBC advocacy.

About the Author

Layla Zulfa

Author

View All Posts

Post navigation

Previous: The Dawn of De-escalation: CompassHER2-pCR Trial Signals a Paradigm Shift in HER2-Positive Breast Cancer Treatment
Next: Navigating the Intersection of GLP-1 Medications and Breast Cancer: What the Latest Research Suggests

Related Stories

navigating-the-intersection-of-glp-1-medications-and-breast-cancer-what-the-latest-research-suggests
  • Patient Advocacy and Support

Navigating the Intersection of GLP-1 Medications and Breast Cancer: What the Latest Research Suggests

Iffa Jayyana October 16, 2026
the-dawn-of-de-escalation-compassher2-pcr-trial-signals-a-paradigm-shift-in-her2-positive-breast-cancer-treatment
  • Patient Advocacy and Support

The Dawn of De-escalation: CompassHER2-pCR Trial Signals a Paradigm Shift in HER2-Positive Breast Cancer Treatment

Sagoh October 16, 2026
precision-de-escalation-compassher2-pcr-trial-signals-a-paradigm-shift-in-her2-positive-breast-cancer-treatment
  • Patient Advocacy and Support

Precision De-escalation: CompassHER2-pCR Trial Signals a Paradigm Shift in HER2-Positive Breast Cancer Treatment

Asro October 16, 2026

Recent Posts

  • Olympus Under Regulatory Siege: FDA Warning Letter Triggers Market Turbulence
  • Groundbreaking Research from OU Uncovers How Aggressive Breast Cancer Manipulates Immune System to Fuel Growth, Paving Way for Novel Therapies
  • Verastem Oncology Set to Advance KRAS Inhibitor VS-7375 to Phase III Trials Following Promising Data in Pancreatic, Colorectal, and Lung Cancers
  • Navigating the Intersection of GLP-1 Medications and Breast Cancer: What the Latest Research Suggests
  • A Global Beacon of Hope: 325 Landmarks to Illuminate for National Metastatic Breast Cancer Awareness Day

Recent Comments

No comments to show.

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

olympus-under-regulatory-siege-fda-warning-letter-triggers-market-turbulence
  • Treatment Innovations

Olympus Under Regulatory Siege: FDA Warning Letter Triggers Market Turbulence

Pevita Pearce October 16, 2026
groundbreaking-research-from-ou-uncovers-how-aggressive-breast-cancer-manipulates-immune-system-to-fuel-growth-paving-way-for-novel-therapies
  • Medical Research and Clinical Trials

Groundbreaking Research from OU Uncovers How Aggressive Breast Cancer Manipulates Immune System to Fuel Growth, Paving Way for Novel Therapies

Azzam Bilal Chamdy October 16, 2026
verastem-oncology-set-to-advance-kras-inhibitor-vs-7375-to-phase-iii-trials-following-promising-data-in-pancreatic-colorectal-and-lung-cancers
  • Medical Research and Clinical Trials

Verastem Oncology Set to Advance KRAS Inhibitor VS-7375 to Phase III Trials Following Promising Data in Pancreatic, Colorectal, and Lung Cancers

Nana Muazin October 16, 2026
navigating-the-intersection-of-glp-1-medications-and-breast-cancer-what-the-latest-research-suggests
  • Patient Advocacy and Support

Navigating the Intersection of GLP-1 Medications and Breast Cancer: What the Latest Research Suggests

Iffa Jayyana October 16, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.